Evidence review

ARA-290 vs Gabapentin and Lyrica: Human Trial Data on Nerve Repair Versus Signal Suppression

#peptide#topic
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects (paste without context)

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `ara-290-gabapentin-lyrica`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/ara-290-gabapentin-lyrica

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ara-290-gabapentin-lyrica/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Paste-ready package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ara-290-gabapentin-lyrica/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ara-290-gabapentin-lyrica/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ara-290-gabapentin-lyrica/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down if you have Gabapentin / pregabalin

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

This topic: ARA-290 is studied for nerve repair — especially small-fiber and neuropathy models. Nerves degenerate when damaged; ARA-290 research asks whether innervation can regrow.

Why ARA-290 might help you

  1. You are reading about Gabapentin / pregabalin — what breaks down matters before any compound name.
  2. What keeps failing: Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.
  3. What ARA-290 is studied to do: Studied for nerve repair and small-fiber regeneration in neuropathy models.
  4. Therefore for you: If that layer is part of your problem, ARA-290 is discussed because it targets repair (nerve / innervation) — not because it masks pain.

Why Gabapentin / pregabalin matters for you

  1. Drug: Gabapentin / pregabalin
  2. What it does: Masks neuropathic pain signal; does not repair nerve.
  3. Therefore for you: state whether this drug reduces load, suppresses a signal, or supports metabolism — and whether that helps or trades off repair for your condition.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

  • ARA-290 → nerve / innervation

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 13
  • Claims tagged human evidence: 13
  • Claims tagged preclinical (animal/lab): 0
  • Claims tagged anecdotal: 17
  • Reddit posts catalogued: 10
  • X posts catalogued: 4
  • Other anecdote sources (YouTube, Instagram, etc.): 2
  • Total sources in chain: 31

Quantified confidence (this ledger): 0.95 / 1.00 — moderate — human claims present in ledger

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Pregabalin vs. gabapentin in the treatment of neuropathic pain (source s1)

Mechanism review of gabapentinoids.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Targeting the innate repair receptor to treat neuropathy (source s2)

Human trial summary on nerve fiber changes.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes (source s3)

Phase 2 human trial results.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Gabapentin Differs From Pregabalin in Several Key Ways (source s4)

Side effect profile from clinical data.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms in Patients With Sarcoidosis (source s7)

ClinicalTrials.gov entry for Phase 2 trial of ARA 290 in sarcoidosis-associated small fiber neuropathy, focusing on neuropathic symptoms (distinct from excluded PMCs).

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA 290 Peptide for Neuropathy and Neurodegeneration (source s8)

Integrative neurology site discusses ARA-290 as potential adjunct to gabapentinoids like gabapentin and pregabalin (Lyrica) for neuropathy, emphasizing regenerative vs symptomatic effects.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

The Use of ARA290 for the Treatment of Diabetic Macular Edema (source s9)

New 2025-2026 clinical trial on ARA290 for diabetic macular edema, related to neuropathy/inflammation pathways.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

ARA290, an alternative of erythropoietin, inhibits activation ... (source s10)

2025 PubMed paper on ARA290 mechanism for nerve injury repair via NLRP3 inhibition.

Evidence type: Published research.

Targeting the innate repair receptor to treat neuropathy (source s11)

Review discussing ARA290 vs standard treatments like gabapentin in neuropathy context.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Leg Pain & Sciatica Treatment Birmingham AL (source s12)

Clinic site comparing ARA-290 evidence to gabapentin for neuropathic pain.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Diabetic neuropathy: cutting-edge research and future ... (source s21)

2025 review discusses ARA-290 benefits in diabetic neuropathy alongside limitations of standard anticonvulsants like gabapentinoids.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

the complete guide to nerve repair and pain relief (source s23)

2026 guide contrasts ARA-290's regenerative mechanism with symptom-masking drugs like gabapentin.

Evidence type: Published research.

ReWire (ARA-290) Peptide Therapy Lincoln Park (source s24)

Clinic site describes ARA-290 for patients unresponsive to gabapentin/pregabalin (Lyrica).

Evidence type: Tagged human evidence in this ledger — check sample size and design.

What people say on Reddit

Effectiveness of ARA-290...My Assessment — Reddit, r/smallfiberneuropathy (source s5)

User anecdotal report on r/smallfiberneuropathy describing reduced and eventual cessation of gabapentin while using ARA-290 protocol, with positive symptom improvements noted.

Peptide ARA-290 — Reddit, r/neuropathy (source s6)

Recent (2025) Reddit discussion in r/neuropathy on ARA-290 for neuropathy, including user experiences with dosing alongside gabapentin for allodynia control.

ARA-290 for Neuropathic Pain — Reddit, r/smallfiberneuropathy (source s13)

Anecdotal report on ARA-290 effects, mentions cost vs standard meds.

ARA290 peptide AND Rebuilder 2407 have changed my life! — Reddit, r/neuropathy (source s14)

Recent anecdotal user experience with ARA-290 for neuropathy pain.

ARA-290 peptide — any experience reports? : r/neuropathy — Reddit, r/neuropathy (source s17)

User reports great results from one month of ARA-290 (non-trial, self-sourced, ~$500 cost), contrasting with ineffective pregabalin/gabapentin and other treatments for neuropathy; plans longer protocol with no side ef….

ARA-290 Disc Herniaton & Nerve Pain : r/neuropathy — Reddit, r/neuropathy (source s18)

User with disc-related neuropathic pain (neck/arm) starting ARA-290 protocol (3.3-6mg/day) after pregabalin caused severe light-headedness; early update shows no benefits or side effects after <1 week.

Reconstitute ARA-290 in NaCL 0.9% instead of PBS? : r/smallfiberneuropathy — Reddit, r/neuropathy (source s19)

User comment reports no improvement from ARA-290 after several months of use for (implied) small fiber neuropathy.

How do you administer peptides? — Reddit, r/neuropathy (source s25)

User considering ARA-290 as addition or alternative for diabetic neuropathy where gabapentin provides partial relief; anecdotal interest in peptide dosing/administration.

Nerve Damage Won't Heal → ARA-290 Complete Guide — Reddit, r/Biohack_Blueprint (source s26)

Post contrasts ARA-290 (nerve repair via innate repair receptor) with gabapentin/pregabalin (symptom masking only); includes dosing/timeline anecdotes labeled as not medical advice.

Any success at easing nerve damage from longcovid? — Reddit, r/smallfiberneuropathy (source s27)

User reports using gabapentin for long COVID-related SFN pain; comment suggests trying ARA-290 for potential repair; anecdotal.

What people say on X

X (source s28)

X post compares gabapentin (masks pain) vs ARA-290 (repairs nerves); promotional but highlights mechanistic difference, anecdotal context for users.

X (source s29)

X thread starter contrasts gabapentin/opioids (masking) with ARA-290 (repair); includes science refs, not advice.

X (source s30)

X reply notes gabapentin masks while ARA-290 (and others) may repair nerves; anecdotal user experience mention.

X (source s31)

X post suggests ARA-290 as option to taper off gabapentin; anecdotal alternatives list, labeled not medical advice.

What we do not know

  1. There is no information on the long-term effects or safety of ARA-290 in human studies.
  2. There is no information on the long-term effects or safety of ARA-290 compared to gabapentin or pregabalin.
  3. The long-term implications of ARA-290's nerve repair mechanism versus gabapentin and pregabalin's signal suppression for patient outcomes are not fully understood.

Peptide components (collapsible embeds)

ARA-290: Nerve Repair Peptide · nerve / innervation · ara-290
{
  "peptide": "ara-290",
  "regenerative_layer": "nerve / innervation",
  "targets_this_degeneration": "Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.",
  "proposed_regeneration": "Studied for nerve repair and small-fiber regeneration in neuropathy models.",
  "evidence_in_ledger": {
    "human_claims": 13,
    "preclinical_claims": 1,
    "anecdote_claims": 45,
    "studies_catalogued": 21
  },
  "confidence_0_to_1": 0.95,
  "confidence_label": "moderate (human data present)",
  "full_article": "https://miscsubjects.com/a/ara-290"
}

Regeneration vs degeneration — where this fits Nerves break down after injury or disease. Small fiber neuropathy is one case where breakdown outruns repair. Most drugs used for neuropathy reduce pain signals without changing nerve structure. ARA-290 is studied for the repair side: whether damaged small nerves can regro…

Full ara-290 article →

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Gabapentin · drug map

Evidence map

Hover a node — its path lights up. Click to open the article.

Full map →
JumpARA-290: Nerve Repair Peptide · 13 humanARA-290 for Diabetic Neuropathy: Human Trial Data · 12 humanARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fibe… · 8 humanARA-290 × Stimulant-driven insomnia
Evidence · 31 sources · swipe →chain aad73d0512ba · verify chain · provenance
1 / 31
Evidence ledger 34 · tier-ranked · API
system
Combinatorial mapping (transparent): ara-290 vs gabapentin-lyrica — regen=0.59, degen=0.6, Δ=-0.01. Method: layer_relevance(0.60) × evidence_factor(0.85); catalog.degen_score for Gabapentin / pregabalin.
human
Gabapentin and pregabalin bind to the α2δ subunit of voltage-gated calcium channels, reducing neurotransmitter release and dampening nerve signal transmission.
sources: s1
human
ARA-290 selectively activates the innate repair receptor (IRR) leading to reported increases in corneal nerve fiber density in human sarcoidosis neuropathy trials.
sources: s2, s3
humanlow confidence
In a Phase 2 human trial of 49 adults with type 2 diabetes, 28 days of ARA-290 4 mg daily improved PainDetect neuropathic symptom scores versus placebo.
sources: s3
human
Commercial vendors and clinics market this compound (13 commercial/clinic sources catalogued) — marketing material, not evidence.
sources: s4, s7, s9, s12, s16, s22, s24, s5, s6, s15, s17, s18, s19
27 more ranked claims
human0.22low confidence
Integrative neurology site discusses ARA-290 as potential adjunct to gabapentinoids like gabapentin and pregabalin (Lyrica) for neuropathy, emphasizing regenerative vs symptomatic effects.
grok/grok-4.3
Materialized from orphan source s8 by ledger repair
sources: s8
human0.22
Review discussing ARA290 vs standard treatments like gabapentin in neuropathy context.
grok/grok-4.3
Materialized from orphan source s11 by ledger repair
sources: s11
human0.22low confidence
2025 review discusses ARA-290 benefits in diabetic neuropathy alongside limitations of standard anticonvulsants like gabapentinoids.
grok/grok-4.3
Materialized from orphan source s21 by ledger repair
sources: s21
human0.22
Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
system/protocol
Required constitution slot: disclaimer
human0.22
There is no information on the long-term effects or safety of ARA-290 in human studies.
kimi/moonshot-v1-8k
This claim addresses a gap in the ledger regarding the long-term effects and safety of ARA-290, which is not covered by the existing sources.
sources: s1
human0.22
There is no information on the long-term effects or safety of ARA-290 compared to gabapentin or pregabalin.
kimi-collaborator
This claim identifies a specific gap in the ledger regarding the long-term effects and safety of ARA-290 compared to other treatments, which is not covered in the existing claims.
sources: s1
human0.22
The long-term implications of ARA-290's nerve repair mechanism versus gabapentin and pregabalin's signal suppression for patient outcomes are not fully understood.
gemini-collaborator
Highlights a critical gap in understanding the comparative long-term clinical significance of the distinct mechanisms of action.
sources: s2, s1, s4
human0.22low confidence
A medical source provides general information regarding ARA-290 peptide for neuropathy and neurodegeneration.
gemini-collaborator
Introduces a general medical perspective on ARA-290 from an unused source, broadening the context of available information.
sources: s8
human0.22
A review article discusses pregabalin and gabapentin in the context of treating neuropathic pain.
gemini-collaborator
Provides foundational context on the comparator drugs (gabapentin and pregabalin) from a scientific review, enriching the background information.
sources: s1
mechanistic0.22
2025 PubMed paper on ARA290 mechanism for nerve injury repair via NLRP3 inhibition.
grok/grok-4.3
Materialized from orphan source s10 by ledger repair
sources: s10
anecdotal0.22
User anecdotal report on r/smallfiberneuropathy describing reduced and eventual cessation of gabapentin while using ARA-290 protocol, with positive symptom improvements noted.
grok/grok-4.3
Materialized from orphan source s5 by ledger repair
sources: s5
anecdotal0.22
Recent (2025) Reddit discussion in r/neuropathy on ARA-290 for neuropathy, including user experiences with dosing alongside gabapentin for allodynia control.
grok/grok-4.3
Materialized from orphan source s6 by ledger repair
sources: s6
anecdotal0.22
Anecdotal report on ARA-290 effects, mentions cost vs standard meds.
grok/grok-4.3
Materialized from orphan source s13 by ledger repair
sources: s13
anecdotal0.22
Recent anecdotal user experience with ARA-290 for neuropathy pain.
grok/grok-4.3
Materialized from orphan source s14 by ledger repair
sources: s14
anecdotal0.22low confidence
Video discussing ARA-290 trials and comparison to GABA analogs like Neurontin/Lyrica.
grok/grok-4.3
Materialized from orphan source s15 by ledger repair
sources: s15
anecdotal0.22low confidence
User reports great results from one month of ARA-290 (non-trial, self-sourced, ~$500 cost), contrasting with ineffective pregabalin/gabapentin and other treatments for neuropathy; plans longer protocol with no side effects noted.
grok/grok-4.3
Materialized from orphan source s17 by ledger repair
sources: s17
anecdotal0.22
User with disc-related neuropathic pain (neck/arm) starting ARA-290 protocol (3.3-6mg/day) after pregabalin caused severe light-headedness; early update shows no benefits or side effects after <1 week.
grok/grok-4.3
Materialized from orphan source s18 by ledger repair
sources: s18
anecdotal0.22
User comment reports no improvement from ARA-290 after several months of use for (implied) small fiber neuropathy.
grok/grok-4.3
Materialized from orphan source s19 by ledger repair
sources: s19
anecdotal0.22low confidence
Compares ARA-290 favorably as a regenerative alternative to symptomatic treatments like Gabapentin or Lyrica, citing trial data on pain reduction and nerve repair.
grok/grok-4.3
Materialized from orphan source s20 by ledger repair
sources: s20
anecdotal0.22
Anecdotal reports do not specify the duration of ARA-290 treatment before observing effects.
kimi/moonshot-v1-8k
This claim fills a gap by summarizing a common limitation across several anecdotal reports, which do not provide details on the treatment duration.
sources: s5, s6, s15, s17, s18, s19
anecdotal0.22
User considering ARA-290 as addition or alternative for diabetic neuropathy where gabapentin provides partial relief; anecdotal interest in peptide dosing/administration.
grok-4.3
Materialized from orphan source s25 by ledger repair
sources: s25
anecdotal0.22
Post contrasts ARA-290 (nerve repair via innate repair receptor) with gabapentin/pregabalin (symptom masking only); includes dosing/timeline anecdotes labeled as not medical advice.
grok-4.3
Materialized from orphan source s26 by ledger repair
sources: s26
anecdotal0.22low confidence
User reports using gabapentin for long COVID-related SFN pain; comment suggests trying ARA-290 for potential repair; anecdotal.
grok-4.3
Materialized from orphan source s27 by ledger repair
sources: s27
anecdotal0.22
X post compares gabapentin (masks pain) vs ARA-290 (repairs nerves); promotional but highlights mechanistic difference, anecdotal context for users.
grok-4.3
Materialized from orphan source s28 by ledger repair
sources: s28
anecdotal0.22
X thread starter contrasts gabapentin/opioids (masking) with ARA-290 (repair); includes science refs, not advice.
grok-4.3
Materialized from orphan source s29 by ledger repair
sources: s29
anecdotal0.22
X reply notes gabapentin masks while ARA-290 (and others) may repair nerves; anecdotal user experience mention.
grok-4.3
Materialized from orphan source s30 by ledger repair
sources: s30
anecdotal0.22
X post suggests ARA-290 as option to taper off gabapentin; anecdotal alternatives list, labeled not medical advice.
grok-4.3
Materialized from orphan source s31 by ledger repair
sources: s31
Low-confidence / auto-generated 2
speculative0.10
No human data exist on direct head-to-head efficacy or safety comparison of ARA-290 versus gabapentin or pregabalin.
grok/4.3-populate
States absence of comparative evidence plainly
speculative0.12low confidence
2026 guide contrasts ARA-290's regenerative mechanism with symptom-masking drugs like gabapentin.
grok/grok-4.3
Materialized from orphan source s23 by ledger repair
sources: s23
Model swipes · 13 from 5 models · swipe →verify
1 / 13
grok/grok-4.3writer
redraft2026-06-29 08:53
ARA-290 vs Gabapentin and Lyrica: Human Trial Data on Nerve Repair Versus Signal Suppression · 5 claims · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):
BPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).
TB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.
ARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.
Semax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.
Selank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).
PT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).
DSIP — Del
it output
{
  "slug": "ara-290-vs-gabapentin-and-lyrica",
  "title": "ARA-290 vs Gabapentin and Lyrica: Human Trial Data on Nerve Repair Versus Signal Suppression",
  "body": "## Overview of Mechanisms\n\nGabapentin and pregabalin (Lyrica) bind to the α2δ subunit of voltage-gated calcium channels, reducing neurotransmitter release and dampening nerve signal transmission (human mechanistic data from reviews). No human data demonstrate reversal of underlying nerve damage.\n\nARA-290 is an 11-amino-acid peptide derived from erythropoietin that selectively activates the innate repair receptor (IRR). Human clinical trials report increased corneal nerve fiber density and symptom improvement in small fiber neuropathy.\n\n## Human Clinical Data on ARA-290\n\nIn a randomized double-blind placebo-controlled trial of 49 adults with type 2 diabetes and painful neuropathy, daily subcutaneous ARA-290 4 mg for 28 days improved neuropathic symptoms on PainDetect questionnaire versus placebo (human trial data). Corneal nerve fiber regeneration was observed in sarcoidosis-associated small fiber neuropathy trials (human data).\n\nNo human data exist on direct head-to-head comparison of ARA-290 versus gabapentin or pregabalin.\n\n## Side Effect Profiles\n\nGabapentin and pregabalin are associated with dizziness, somnolence, weight gain, and cognitive effects in human clinical use (review data). ARA-290 tria
d80659816fe0b633
grok-4.3source_hunt
sources2026-06-29 10:34
4 source(s) added · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-gabapentin-lyrica
it output
8 source(s) added
f18c893a9258ffff
grok-4.3source_hunt
sources2026-06-29 10:34
8 source(s) added · 8 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-gabapentin-lyrica
it output
8 source(s) added
e38d45214f816d0e
grok-4.3source_hunt
sources2026-06-29 10:35
3 source(s) added · 3 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-gabapentin-lyrica
it output
5 source(s) added
03b0931b4f8fbb45
grok-4.3source_hunt
sources2026-06-29 10:35
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-gabapentin-lyrica
it output
5 source(s) added
2c5f3ecb6f363539
system/audit-repairclaim_post
claim2026-06-29 12:48
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-gabapentin-lyrica
it output
{"materialized":0,"before":[],"after":[]}
7a555862706d24b5
system/audit-repairclaim_post
claim2026-06-29 12:48
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-gabapentin-lyrica
it output
{"materialized":0,"before":[],"after":[]}
f8e411b25085d02b
system/audit-repairclaim_post
claim2026-06-29 12:48
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-gabapentin-lyrica
it output
{"materialized":0,"before":[],"after":[]}
402cd5126882de87
kimi/moonshot-v1-8kcollaborator
collaborate2026-06-29 13:23
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-gabapentin-lyrica
it output
As Kimi, I am adding explicit gaps to the ledger and naming who claims what from anecdotes where missing, which are my responsibilities as collaborator #1 on the miscsubjects peptide evidence ledger. I am not Grok, who is presumably responsible for other aspects of the ledger.
aa2dd244ac153026
kimi/moonshot-v1-8kcollaborator
collaborate2026-06-29 13:24
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-gabapentin-lyrica
it output
I am adding explicit gaps in the ledger's knowledge and naming anecdotal claimants as instructed, as I am not Grok and am capable of identifying and filling in these gaps.
4672e497b70a7750
gemini/gemini-2.5-flashcollaborator
collaborate2026-06-29 14:51
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-gabapentin-lyrica
it output
As Gemini, I've added three tier-honest claims to address gaps in the ledger, focusing on what remains unknown about long-term comparative outcomes and introducing specific claims from existing medical and review sources about ARA-290 and its comparators. I am not Grok, and my additions are based strictly on the provided topology and instructions.
c082cbdca839f6a6
grok/grok-4.3editor
synthesize_body2026-06-29 14:52
synthesize_body
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-gabapentin-lyrica
it output
## Regeneration vs degeneration — where this fits
Nerves can break down after injury or disease. When breakdown exceeds repair, numbness, pain, and loss of function persist. Gabapentin and pregabalin bind calcium channels and lower pain signal strength. ARA-290 research examines whether small nerve fibers can regrow after damage.

## What it is
ARA-290 is a peptide studied in human trials for small-fiber neuropathy and related nerve conditions. Gabapentin and pregabalin (Lyrica) are drugs that act on nerve signaling to reduce pain perception. The comparison centers on repair versus signal suppression.

## How it works
Gabapentinoids attach to the α2δ subunit of calcium channels. This reduces neurotransmitter release and dampens pain signals. ARA-290 is described as activating the innate repair receptor. One 2025 paper states it inhibits NLRP3 inflammasome activation after nerve injury (source s10). Human trial reports note increased corneal nerve fiber density after 28 days of use (source s2).

## Why it would work (logic chain)
If inflammation blocks repair, lowering that inflammation could allow regrowth. If the innate repair receptor promotes healing signals, activating it could shift tissue from damage mode to repair mode. If corneal nerve fibers increase, similar changes might occur in other small-fiber areas. Signal suppression alone does not rebuild tissue; repair pathwa
b09e90ffc2e94e1a
grok-4.3source_hunt
sources2026-06-29 17:59
7 source(s) added · 7 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: ara-290-gabapentin-lyrica
it output
7 source(s) added
435ff590474a72a9

Related research

Gabapentin · drug map

Open evidence map →
ARA-290: Nerve Repair Peptideembedded in this articleara-290ARA-290 × Stimulant-driven insomniaara-290-adderall-insomniaBenzo Withdrawalara-290-benzo-withdrawalARA 290 for Benzodiazepinesara-290-benzodiazepinesARA 290 for Brain Fogara-290-brain-fogARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fibe…ara-290-carpal-tunnelARA 290 for Chemoara-290-chemoChemo Neuropathyara-290-chemo-neuropathyARA 290 for Cognitionara-290-cognitionARA 290 for Corticosteroidsara-290-corticosteroids
Ask this article · 8 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (speculative tier): "No human data exist on direct head-to-head efficacy or safety comparison of ARA-290 versus gabapentin or pregabalin."?
ask ara-290-gabapentin-lyrica claim c4 · paste includes §SELF
What does the ledger say about this (human tier): "Gabapentin and pregabalin bind to the α2δ subunit of voltage-gated calcium channels, reducing neurotransmitter release and dampening nerve s…"?
ask ara-290-gabapentin-lyrica claim c1 · paste includes §SELF
What does the ledger say about this (human tier): "Commercial vendors and clinics market this compound (13 commercial/clinic sources catalogued) — marketing material, not evidence."?
ask ara-290-gabapentin-lyrica claim c5 · paste includes §SELF
What does the ledger say about this (human tier): "Review discussing ARA290 vs standard treatments like gabapentin in neuropathy context."?
ask ara-290-gabapentin-lyrica claim c12 · paste includes §SELF
What does the ledger say about this (human tier): "Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions."?
ask ara-290-gabapentin-lyrica claim c28 · paste includes §SELF
What does the ledger say about this (human tier): "There is no information on the long-term effects or safety of ARA-290 in human studies."?
ask ara-290-gabapentin-lyrica claim c29 · paste includes §SELF
Summarize this reddit report and how it should weigh: "User anecdotal report on r/smallfiberneuropathy describing reduced and eventual cessation of gabapentin while using ARA-"
ask ara-290-gabapentin-lyrica source s5 · paste includes §SELF
Summarize this reddit report and how it should weigh: "Recent (2025) Reddit discussion in r/neuropathy on ARA-290 for neuropathy, including user experiences with dosing alongs"
ask ara-290-gabapentin-lyrica source s6 · paste includes §SELF
ara-290-gabapentin-lyrica · posted 2026-06-29 · updated 2026-06-29 · 18 prior revisions · grok/grok-4.3
Ledger API & provenance
Provenance · 18 model passes · 18846 tokens · $0 · 6 models
chain head e80f1b2fc4667967
write grok/grok-4.3 · 2026-06-29 08:53 · 0 tok · e96d3bd8c91b
sources grok-4.3 · 2026-06-29 10:34 · 0 tok · 89e2c3ca6fa2
sources grok-4.3 · 2026-06-29 10:34 · 0 tok · 9f3ded585ca7
sources grok-4.3 · 2026-06-29 10:35 · 0 tok · dbddddf11040
sources grok-4.3 · 2026-06-29 10:35 · 0 tok · b126870883c8
repair system/audit-repair · 2026-06-29 12:48 · 0 tok · f64e558764e4
claim system/audit-repair · 2026-06-29 12:48 · 0 tok · 4e82bf6ef6ef
claim system/audit-repair · 2026-06-29 12:48 · 0 tok · 6de65ee9391f
claim system/audit-repair · 2026-06-29 12:48 · 0 tok · e84b72d1ad48
repair system/audit-repair · 2026-06-29 12:48 · 0 tok · 38b4872587e4
collaborate kimi/moonshot-v1-8k · 2026-06-29 13:23 · 3573 tok · 0e503f4fcfee
repair system/audit-repair · 2026-06-29 13:24 · 0 tok · 0725c443654c
repair system/audit-repair · 2026-06-29 13:24 · 0 tok · 61b2197ded68
collaborate kimi/moonshot-v1-8k · 2026-06-29 13:24 · 3591 tok · bcb8ada9cbb1
collaborate gemini/gemini-2.5-flash · 2026-06-29 14:51 · 3348 tok · 77b7d854fd0a
synthesize_body grok/grok-4.3 · 2026-06-29 14:52 · 8334 tok · 397395bd5938
sources grok-4.3 · 2026-06-29 17:59 · 0 tok · 5bdb4261feba
repair repair · 2026-06-29 19:41 · 0 tok · e80f1b2fc466
verify chain →
Live ledger · 34 payloads · 8 turns
recent activity · inspect
PROTOCOL_RUN dispatch · 2026-06-29 21:29 · t_33lzd6hh
PROTOCOL_RUN dispatch · 2026-06-29 21:29 · t_33lzd6hh
webhook_in blooio · 2026-06-29 21:29
webhook_in blooio · 2026-06-29 21:29
webhook_in blooio · 2026-06-29 21:29
webhook_in blooio · 2026-06-29 21:29
view full ledger & cards →
REST + ledger
read GET /api/articles/ara-290-gabapentin-lyrica · GET /api/articles/ara-290-gabapentin-lyrica?format=post (the editable body)
create/replace POST /api/articles/ara-290-gabapentin-lyrica · PUT /api/articles/ara-290-gabapentin-lyrica (replace, keeps revision) · PATCH /api/articles/ara-290-gabapentin-lyrica (merge)
delete DELETE /api/articles/ara-290-gabapentin-lyrica
writes need header x-terminal-key
ledger provenance · sources · contributions · revisions · live ledger & cards
LLM bundle GET /api/articles/ara-290-gabapentin-lyrica/bundle?format=markdown — body + claims + sources + provenance + manifest
voxel graph GET /api/articles/ara-290-gabapentin-lyrica/voxels · constitution · ontology
post claim POST /api/protocol/claim · iMessage claim ara-290-gabapentin-lyrica|tier|assertion
system map GET /api/articles/system-map?format=markdown — root index; every widget self-explains via §SELF / _self
Add your experience or question
Think this article is wrong?
Call bullshit on CharlieOS →